![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Jaques , MC Tobes, JC Sisson, JA Baker and DM Wieland
Radioiodinated meta-iodobenzylguanidine (MIBG), a scintigraphic agent used for the detection of human pheochromocytomas, is thought to utilize the same uptake and retention mechanism(s) as norepinephrine (NE). Using cultured bovine adrenomedullary cells, we compared the mechanism(s) of uptake of MIBG to that of NE. Two different uptake systems were identified. NE and MIBG were taken up by a sodium- dependent system that was characterized by: 1) temperature dependency; 2) high affinity: Km of 1.22 +/- 0.12 microM for MIBG and 1.41 +/- 0.50 microM for NE; 3) low capacity: Vm (picomoles/10(6) cells/10 min) of 64.3 +/- 3.3 for MIBG and 36.6 +/- 7.2 for NE; 4) saturability; 5) ouabain sensitivity; and 6) energy dependency. However, NE and MIBG also were taken up by a temperature-dependent, sodium-independent, apparently unsaturable, and energy-independent system. The sodium- dependent uptake system fulfills many of the criteria for Uptake1 whereas the sodium-independent uptake system is most likely a passive diffusion process. NE uptake proceeded predominantly by the sodium- dependent process. Uptake of MIBG occurred by both pathways at low concentrations, but at high concentrations (greater than 10 microM) uptake was predominantly (75 to 100%) by the sodium-independent process. Inhibition studies suggest that MIBG and NE are transported by the same carrier involved in the sodium-dependent system. Scintiscans of the human adrenals and pheochromocytomas appear to reflect uptake of [131I]MIBG by the sodium-dependent system.
This article has been cited by other articles:
|
|
 |
|
  A G McCluskey, M Boyd, S L Pimlott, J W Babich, M N Gaze, and R J Mairs Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S28 - S35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Alesci, S. M. Perera, E. W. Lai, C. Kukura, M. Abu-Asab, M. Tsokos, J. C. Morris, and K. Pacak Adenoviral Gene Transfer in Bovine Adrenomedullary and Murine Pheochromocytoma Cells: Potential Clinical and Therapeutic Relevance Endocrinology, August 1, 2007; 148(8): 3900 - 3907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. McCluskey, M. Boyd, S. C. Ross, E. Cosimo, A. M. Clark, W. J. Angerson, M. N. Gaze, and R. J. Mairs [131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter Clin. Cancer Res., November 1, 2005; 11(21): 7929 - 7937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Pashankar, M. S. O'Dorisio, and Y. Menda MIBG and Somatostatin Receptor Analogs in Children: Current Concepts on Diagnostic and Therapeutic Use J. Nucl. Med., January 1, 2005; 46(1_suppl): 55S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Beek, J. A. P. van der Sloot, M. Huikeshoven, H. J. Verberne, B. L. F. van Eck-Smit, J. van der Meulen, J. G. P. Tijssen, M. J. C. van Gemert, and R. Tukkie Cardiac denervation after clinical transmyocardial laser revascularization: Short-term and long-term iodine 123-labeled meta-iodobenzylguanide scintigraphic evidence J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 517 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Carlin, R. J. Mairs, A. G. McCluskey, D. A. Tweddle, A. Sprigg, C. Estlin, J. Board, R. E. George, C. Ellershaw, A. D. J. Pearson, et al. Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[131I]iodobenzylguanidine by Neuroblastoma Tumors Clin. Cancer Res., August 1, 2003; 9(9): 3338 - 3344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Ogita, T Shimonagata, M Fukunami, K Kumagai, T Yamada, Y Asano, A Hirata, M Asai, H Kusuoka, M Hori, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study Heart, December 1, 2001; 86(6): 656 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Jonker, E. Wagenaar, C. A. A. M. Mol, M. Buitelaar, H. Koepsell, J. W. Smit, and A. H. Schinkel Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene Mol. Cell. Biol., August 15, 2001; 21(16): 5471 - 5477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Braune, M. Reinhardt, R. Schnitzer, A. Riedel, and C. H. Lucking Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy Neurology, September 1, 1999; 53(5): 1020 - 1020. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
